OncoGenex to Present at the Needham & Company 10th Annual Healthcare Conference
BOTHELL, Wash. and VANCOUVER, British Columbia – March 29, 2011 – OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex’ president and chief executive officer, will provide a corporate presentation at the Needham & Company 10th Annual Healthcare Conference on Wednesday, April 6 at 2:40 p.m. ET.
The corporate presentation will be webcast live and can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. A webcast replay will be available approximately one hour after the call and will be archived for 90 days.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex’ lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.
More information about OncoGenex is available at www.oncogenex.com.